BioLineRx joins immuno-oncology scrum through Keytruda combo deal

Nick Paul Taylor BioLineRx has become the latest company to stake its claim for a spot on the burgeoning roster of immuno-oncology combinations. The small biotech is aiming to muscle ...

With $1B in VC cash, Intarcia is happy to stay out of the IPO scrum

Damian Garde Intarcia Therapeutics is rolling toward an FDA application with its long-acting diabetes treatment, but despite the ready availability of IPO cash for drug developers, ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS